Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-07-17

Catalyst Pharmaceuticals (CPRX)

CEO Richard Daly was paid $7,774,160 in fiscal year 2024, the 13th percentile of its disclosed peer group (SEC filing 0001193125-25-079097 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,774,160
Richard Daly total, FY2024
13th
CEO pay percentile vs peers
21:1
CEO-to-median pay ratio
92.73%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Richard Daly (President and CEO), FY2024 total compensation $7,774,160 (base salary $750,000) [exec_comp, SEC accession 0001193125-25-079097, filed 2025-04-11]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Richard Daly$750,000$590,625$1,267,601$5,070,830$0$0$95,104$7,774,160
President and CEO
Michael Kalb525,000350,6251,036,8034,147,34500121,1636,180,936
EVP and CFO
Steven Miller560,000352,800523,7972,095,3770013,8003,545,774
COO and CSO
Jeffrey Del Carmen525,000275,625355,0061,420,1240062,3722,638,127
CCO
Preethi Sundaram485,000254,625355,0061,420,1240013,8002,528,555
Chief Strategy Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Richard Daly$7,774,160———
Michael Kalb6,180,936———
Steven Miller3,545,7743,404,6983,474,783↑ +141,076
Jeffrey Del Carmen2,638,1272,506,0662,386,432↑ +132,061
Preethi Sundaram2,528,5552,145,7982,138,461↑ +382,757

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Catalyst Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CPRX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CPRX
16 companies name CPRX as a compensation peer

Each company listed discloses CPRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CPRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Charles B. O'KeeffeDirector$408,644
David S. TierneyIndependent Director$381,019
Donald A. DenkhausIndependent Director$386,269
Molly HarperIndependent Director$439,144
Patrick J. McEnanyChair of the Board$844,759
Tamar ThompsonIndependent Director$381,019
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Patrick J. McEnanyDirector2025-11-21A1,775——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2025-11-21D2,485——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2025-11-21A6,894——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-11-21A5,603——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-11-21D5,16100Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-11-21D2,030——CommonForm 4 ↗
Richard J. DalyDirector2025-11-21D7,872——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-11-26A10,98300Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-11-26D10,98323256,244CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-11-26A10,983446,238CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-01D45,00000CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-01D45,00000CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-01D45,00000CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-08D1,669——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-08A6,855——CommonForm 4 ↗
Dividend-equivalent accruals2025-12-08—5,652——4 insiders, 4 accrual rows
Molly HarperDirector2025-12-08A1,413——CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-08A3,534——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-08D2,492——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-08A8,039——CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-08A11,873——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-08D7,06700Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-08D6,85500Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-08D8,03900Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-08A7,067——CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-08D11,87300Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2025-12-08A1,413——CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-08D3,53400Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2025-12-08A1,413——CommonForm 4 ↗
David S. TierneyDirector2025-12-08A1,413——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-08D2,780——CommonForm 4 ↗
Molly HarperDirector2025-12-12D6,74623155,563CommonForm 4 ↗
Molly HarperDirector2025-12-12D15,52723360,195CommonForm 4 ↗
Molly HarperDirector2025-12-12A20,0006115,600CommonForm 4 ↗
Molly HarperDirector2025-12-12D20,00000Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2025-12-12D4,47324106,162CommonForm 4 ↗
Dividend-equivalent accruals2025-12-29—5,336——4 insiders, 4 accrual rows
Patrick J. McEnanyDirector2025-12-29D26,33400Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-29D6,786——CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-29D14,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-29A14,000——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-29A6,667——CommonForm 4 ↗
David S. TierneyDirector2025-12-29A1,334——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-29D2,623——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-29D6,66700Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-29D6,66700Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-29A6,667——CommonForm 4 ↗
Donald A. DenkhausDirector2025-12-29A1,334——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-29D8,66700Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-29D3,839——CommonForm 4 ↗
Richard J. DalyDirector2025-12-29D524——CommonForm 4 ↗
Richard J. DalyDirector2025-12-29A1,334——CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-29A26,334——CommonForm 4 ↗
Molly HarperDirector2025-12-29A1,334——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-29D2,369——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-29A8,667——CommonForm 4 ↗
Richard J. DalyDirector2026-01-05D42,10500Derivative, Class A CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2026-01-05A7,139——CommonForm 4 ↗
Richard J. DalyDirector2026-01-05D10,577——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2026-01-05D7,13900Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-01-05A42,105——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2026-01-05D2,080——CommonForm 4 ↗
Dividend-equivalent accruals2026-02-17—687——1 insider, 1 accrual row
Gregg RussoChief HR Officer2026-02-17D211——CommonForm 4 ↗
Gregg RussoChief HR Officer2026-02-17A687——CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-06-03D743——CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-06-03A3,052——CommonForm 4 ↗
Dividend-equivalent accruals2026-07-15—13,232——4 insiders, 8 accrual rows
Gregg RussoChief HR Officer2026-07-15D6,95700Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D39,70100Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D131,53600Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D13,66532430,448CommonForm 4 ↗
Molly HarperDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D3,69432116,361CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D40,01300Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D491,16000Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D30,00000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D32,25700Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D11,20600Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D143,19300Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D11,20600Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D8,03900Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D167,91800Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D200,00000Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D150,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D33,50000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D34,92100Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D740,00000Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D6,19700Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D11,87300Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D158,45400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D275,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D180,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D1,093,8033234,454,795CommonForm 4 ↗
David S. TierneyDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Daniel J. CurranDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Daniel J. CurranDirector2026-07-15D40,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D7,06700Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D147,62100Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D135,00000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D6,85500Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D106,87300Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D43,59100Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D270,00000Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D4763214,994CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D3,77332118,850CommonForm 4 ↗
David S. TierneyDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D33,50000Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D169,24800Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D3,53400Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D12,50000Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D2,3093272,734CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D1,365,31900Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D106,87300Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D67,50000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D54,804321,726,326CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D137,55300Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D135,00000Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D14,33732451,616CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D10,54000Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D16,53400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D202,95800Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D29,77600Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D98,65200Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D126,70400Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D257,21400Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D13,78800Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D98,65200Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D124,44700Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D115,28300Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D381,94800Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D33,50000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D68,00000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D225,00000Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D32,25700Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D88,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D30,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D498,7733215,711,350CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D73,81000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D272,00000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D400,00000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D4,171,55932131,404,109CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D2,75200Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D20,53100Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D20,34900Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D40,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D146,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D185,00000Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D30,00000Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D383,3143212,074,391CommonForm 4 ↗
Daniel J. CurranDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D69,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D200,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D132,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D242,501327,638,782CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D21,41600Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D29,77600Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D271,266328,544,879CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D3,55200Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D47,82600Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D248,00400Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D10,32200Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D12,20900Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D126,31600Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D137,55300Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Patrick J. McEnanyDirector2025-11-21A1,775——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2025-11-21D2,485——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2025-11-21A6,894——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-11-21A5,603——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-11-21D5,16100Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-11-21D2,030——CommonForm 4 ↗
Richard J. DalyDirector2025-11-21D7,872——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-11-26A10,98300Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-11-26D10,98323256,244CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-11-26A10,983446,238CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-01D45,00000CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-01D45,00000CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-01D45,00000CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-08D1,669——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-08A6,855——CommonForm 4 ↗
Molly HarperDirector2025-12-08D1,41300Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2025-12-08A1,413——CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-08A3,534——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-08D2,492——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-08A8,039——CommonForm 4 ↗
Tamar ThompsonDirector2025-12-08D1,41300Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-08A11,873——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-08D7,06700Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-08D6,85500Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-08D8,03900Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-08A7,067——CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-08D11,87300Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2025-12-08A1,413——CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-08D3,53400Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2025-12-08A1,413——CommonForm 4 ↗
David S. TierneyDirector2025-12-08D1,41300Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2025-12-08A1,413——CommonForm 4 ↗
Donald A. DenkhausDirector2025-12-08D1,41300Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-08D2,780——CommonForm 4 ↗
Molly HarperDirector2025-12-12D6,74623155,563CommonForm 4 ↗
Molly HarperDirector2025-12-12D15,52723360,195CommonForm 4 ↗
Molly HarperDirector2025-12-12A20,0006115,600CommonForm 4 ↗
Molly HarperDirector2025-12-12D20,00000Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2025-12-12D4,47324106,162CommonForm 4 ↗
Richard J. DalyDirector2025-12-29D1,33400Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-29D26,33400Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-29D6,786——CommonForm 4 ↗
Molly HarperDirector2025-12-29D1,33400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-29D14,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2025-12-29A14,000——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-29A6,667——CommonForm 4 ↗
David S. TierneyDirector2025-12-29A1,334——CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-29D2,623——CommonForm 4 ↗
Donald A. DenkhausDirector2025-12-29D1,33400Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-29D6,66700Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-29D6,66700Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Compliance/Legal Officer2025-12-29A6,667——CommonForm 4 ↗
Donald A. DenkhausDirector2025-12-29A1,334——CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-29D8,66700Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-29D3,839——CommonForm 4 ↗
Richard J. DalyDirector2025-12-29D524——CommonForm 4 ↗
Richard J. DalyDirector2025-12-29A1,334——CommonForm 4 ↗
Patrick J. McEnanyDirector2025-12-29A26,334——CommonForm 4 ↗
Molly HarperDirector2025-12-29A1,334——CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2025-12-29D2,369——CommonForm 4 ↗
David S. TierneyDirector2025-12-29D1,33400Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2025-12-29A8,667——CommonForm 4 ↗
Richard J. DalyDirector2026-01-05D42,10500Derivative, Class A CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2026-01-05A7,139——CommonForm 4 ↗
Richard J. DalyDirector2026-01-05D10,577——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2026-01-05D7,13900Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-01-05A42,105——CommonForm 4 ↗
Michael KalbExecutive Vice President & CFO2026-01-05D2,080——CommonForm 4 ↗
Gregg RussoChief HR Officer2026-02-17D68700Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-02-17D211——CommonForm 4 ↗
Gregg RussoChief HR Officer2026-02-17A687——CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-06-03D743——CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-06-03A3,052——CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D1,89400Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D6,95700Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D39,70100Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D131,53600Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D13,66532430,448CommonForm 4 ↗
Molly HarperDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D1,41400Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D3,69432116,361CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D40,01300Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D491,16000Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D30,00000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D32,25700Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D11,20600Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D143,19300Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D11,20600Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D8,03900Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D167,91800Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D200,00000Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D150,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D1,41400Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D33,50000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D34,92100Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D740,00000Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D6,19700Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D1,89400Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D11,87300Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D158,45400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D275,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D180,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D1,093,8033234,454,795CommonForm 4 ↗
David S. TierneyDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Daniel J. CurranDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Daniel J. CurranDirector2026-07-15D40,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D7,06700Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D147,62100Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D135,00000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D6,85500Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D106,87300Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D43,59100Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D270,00000Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D4763214,994CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D3,77332118,850CommonForm 4 ↗
David S. TierneyDirector2026-07-15D1,41400Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D33,50000Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D169,24800Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D3,53400Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D12,50000Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D2,3093272,734CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D1,365,31900Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D106,87300Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D67,50000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D54,804321,726,326CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D137,55300Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D135,00000Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D14,33732451,616CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D10,54000Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D16,53400Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D202,95800Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D29,77600Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D98,65200Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D126,70400Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D257,21400Derivative, Class A CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D13,78800Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D1,89400Derivative, Class A CommonForm 4 ↗
Molly HarperDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D98,65200Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D124,44700Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D115,28300Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D381,94800Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D33,50000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D68,00000Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D225,00000Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D32,25700Derivative, Class A CommonForm 4 ↗
Jeffrey Del CarmenChief Commercial Officer2026-07-15D88,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D23,24800Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D20,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D30,00000Derivative, Class A CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D498,7733215,711,350CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D73,81000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D272,00000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D400,00000Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D4,171,55932131,404,109CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D2,75200Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D20,53100Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D20,34900Derivative, Class A CommonForm 4 ↗
Gregg RussoChief HR Officer2026-07-15D15,00000Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D1,41400Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Tamar ThompsonDirector2026-07-15D40,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D146,00000Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D185,00000Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D29,52400Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D30,00000Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D383,3143212,074,391CommonForm 4 ↗
Daniel J. CurranDirector2026-07-15D18,11500Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D69,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D200,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D132,00000Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D242,501327,638,782CommonForm 4 ↗
Michael KalbChief Financial Officer2026-07-15D21,41600Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D29,77600Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D271,266328,544,879CommonForm 4 ↗
Donald A. DenkhausDirector2026-07-15D5,46800Derivative, Class A CommonForm 4 ↗
Patrick J. McEnanyDirector2026-07-15D3,55200Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D47,82600Derivative, Class A CommonForm 4 ↗
Steven MillerChief Op. & Scientific Officer2026-07-15D248,00400Derivative, Class A CommonForm 4 ↗
David S. TierneyDirector2026-07-15D1,89400Derivative, Class A CommonForm 4 ↗
Brian ElsberndChief Legal Officer2026-07-15D10,32200Derivative, Class A CommonForm 4 ↗
William T. AndrewsChief Medical Officer2026-07-15D12,20900Derivative, Class A CommonForm 4 ↗
Richard J. DalyDirector2026-07-15D126,31600Derivative, Class A CommonForm 4 ↗
Preethi SundaramChief Strategy Officer2026-07-15D137,55300Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Jeffrey Del CarmenOPTION2024-11-21——137,553—$1,420,124
Preethi SundaramOPTION2024-11-21——137,553—1,420,124
Richard DalyOPTION2024-11-21——491,160—5,070,830
Steven MillerOPTION2024-11-21——202,958—2,095,377
Michael KalbOPTION2024-01-01——257,214—2,399,996
Michael KalbOPTION2024-11-21——169,248—1,747,349
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Jeffrey Del Carmen$0$0$1,420,1240.0%
Preethi Sundaram001,420,1240.0%
Richard Daly005,070,8300.0%
Steven Miller002,095,3770.0%
Michael Kalb004,147,3450.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Michael KalbOption169,24821.12—
Michael KalbOption257,21416.81—
Steven MillerOption202,95821.12—
Jeffrey Del CarmenOption111,94614.15—
Steven MillerOption165,33614.15—
Richard DalyOption5,00018.59—
Richard DalyOption1,365,31913.3—
Richard DalyOption491,16021.12—
Preethi SundaramOption75,0005.49—
Steven MillerOption48,66718.59—
Jeffrey Del CarmenOption30,0004.7—
Jeffrey Del CarmenOption29,33418.59—
Jeffrey Del CarmenOption137,55321.12—
Preethi SundaramOption22,66718.59—
Preethi SundaramOption95,46214.15—
Preethi SundaramOption137,55321.12—
05

Incentive-plan design — the Compensation Discussion & Analysis

The compensation program is designed to provide a competitive level of base salary reflecting position responsibilities and strategic importance, a cash-based short-term incentive to recognize the achievement of annual goals, and long-term equity incentives to align management with long-term stockholder value creation and retention.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantMercer LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-05-2082,734,9396,484,020203,47292.73%Passed
20242024-05-2184,194,4845,468,681181,67493.9%Passed
20232023-08-2272,610,9912,909,780437,05096.15%Passed
20222022-09-1966,515,5822,124,782111,35296.9%Passed
20212021-12-0359,092,9773,432,904246,62694.51%Passed
20202020-08-2056,150,7721,880,451412,64696.08%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-05-2092.73%a
20242024-05-2193.9%b
20232023-08-2296.15%c

a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

c. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)21 : 1
CEO total compensation$7,774,160
Median employee compensation$370,800
08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Patrick J. McEnanyNot independent · Board Chair$282,211$562,548———$844,759
Molly HarperIndependent · Lead Independent Director · Compensation · Corporate Governance · Nominating139,125300,019———439,144
Charles B. O'KeeffeNot standing for re-election108,625300,019———408,644
Donald A. DenkhausIndependent · Audit (Chair) · Corporate Governance · Nominating86,250300,019———386,269
Tamar ThompsonIndependent · Corporate Governance and Nominating (Chair) · Audit81,000300,019———381,019
David S. TierneyIndependent · Compensation (Chair) · Corporate Governance and Nominating81,000300,019———381,019
Richard J. DalyEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)21,000 / 15,750 / 10,500
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$778,211
Equity awards (grant-date value)$2,062,643
All other compensation$0
Total cost of the board$2,840,854

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Catalyst Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Catalyst Pharmaceuticals.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1PTC Therapeutics, Inc.2025Matthew Klein$958,500$16,593,800$4,399,760$1,294,000$23,266,326
2Halozyme Therapeutics, Inc.2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
3Corcept Therapeutics Incorporated2025Joseph Belanoff1,182,333012,907,718015,303,551
4Insmed Incorporated2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
5Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
6Pacira BioSciences, Inc.2025Frank Lee935,3089,215,5000738,81011,636,917
7Ultragenyx Pharmaceutical, Inc.2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
8Ani Pharmaceuticals, Inc.2025Nikhil Lalwani837,4097,848,71101,572,50010,278,620
9Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
10Amphastar Pharmaceuticals, Inc.2025Jack Yongfeng Zhang950,9113,301,9813,302,024361,0008,309,350
11Acadia Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
12Dynavax Technologies Corporation2024Ryan Spencer835,0014,902,1501,824,299641,9078,210,775
13Harmony Biosciences Holdings, Inc.2025Jeffrey Dayno743,6001,976,5204,599,000558,0007,899,535
14Catalyst Pharmaceuticals2024Richard Daly750,0001,267,6015,070,83007,774,160
15Ironwood Pharmaceuticals, Inc.2025Thomas McCourt867,568411,6960650,6761,948,390
16Collegium Pharmaceutical, Inc.2025Vikram Karnani875,00000835,4061,715,846

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Catalyst Pharmaceuticalsnot disclosednot disclosednot disclosedMercer LLC
Acadia Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Amphastar Pharmaceuticals, Inc.not disclosedOptions 50 · RSU 50not disclosedWillis Towers Watson (WTW)
Ani Pharmaceuticals, Inc.185%RSU 75 · PSU 25Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences IndexPearl Meyer & Partners, LLC
Collegium Pharmaceutical, Inc.127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
Corcept Therapeutics IncorporatedDr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%Stock Options 100not disclosednot disclosed
Dynavax Technologies Corporation102.5%Options 34 · RSU 33 · PSU 33Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology IndexAlpine
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Harmony Biosciences Holdings, Inc.100%not disclosednot disclosedPay Governance
Insmed Incorporated175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Ironwood Pharmaceuticals, Inc.100%RSU 50 · PSU 50not disclosedAlpine Rewards LLC
Pacira BioSciences, Inc.90%RSU 80 · PSU 20NoAon
PTC Therapeutics, Inc.not disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Ultragenyx Pharmaceutical, Inc.44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Catalyst Pharmaceuticals in fiscal 2024?
As disclosed, Richard Daly (President and CEO) was the highest-paid executive at Catalyst Pharmaceuticals in fiscal 2024, with total compensation of $7,774,160.
How does Catalyst Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Richard Daly's total compensation ranked at the 13th percentile of Catalyst Pharmaceuticals's disclosed peer group.
What is Catalyst Pharmaceuticals's CEO-to-median employee pay ratio?
As disclosed, Catalyst Pharmaceuticals's CEO-to-median employee pay ratio was 21:1.
How did shareholders vote on Catalyst Pharmaceuticals's executive compensation?
As disclosed, 92.73% of shareholders supported Catalyst Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Catalyst Pharmaceuticals spend in total on board compensation for fiscal 2024?
As disclosed, Catalyst Pharmaceuticals reported total board compensation of $2,840,854 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Richard DalyDEF 14A2025-04-110001193125-25-079097Section “Executive Compensation”. As printed: 7,774,160. Filing ↗
2Section 01, Michael KalbDEF 14A2025-04-110001193125-25-079097Section “Executive Compensation”. As printed: 6,180,936. Filing ↗
3Section 01, Steven MillerDEF 14A2025-04-110001193125-25-079097Section “Executive Compensation”. As printed: 3,545,774. Filing ↗
4Section 01, Jeffrey Del CarmenDEF 14A2025-04-110001193125-25-079097Section “Executive Compensation”. As printed: 2,638,127. Filing ↗
5Section 01, Preethi SundaramDEF 14A2025-04-110001193125-25-079097Section “Executive Compensation”. As printed: 2,528,555. Filing ↗
6Section 03, Jeffrey Del Carmen OPTIONDEF 14A2025-04-110001193125-25-079097Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r6 · c15 · span 337251–337260
7Section 03, Preethi Sundaram OPTIONDEF 14A2025-04-110001193125-25-079097Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r7 · c15 · span 338583–338592
8Section 03, Richard Daly OPTIONDEF 14A2025-04-110001193125-25-079097Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r2 · c15 · span 331869–331878
9Section 03, Steven Miller OPTIONDEF 14A2025-04-110001193125-25-079097Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r5 · c15 · span 335892–335901
10Section 03, Michael Kalb OPTIONDEF 14A2025-04-110001193125-25-079097Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t75 · r3 · c15 · span 333204–333213
11Section 03, Michael Kalb OPTIONDEF 14A2025-04-110001193125-25-079097Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r4 · c15 · span 334560–334569
12Section 07, pay ratioDEF 14A2025-04-110001193125-25-079097Section “CEO Pay Ratio”. As printed: 21 : 1. Filing ↗
13Section 08, Patrick J. McEnanyDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 844,759. Filing ↗machine: span 167469–167476
14Section 08, Molly HarperDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 439,144. Filing ↗machine: span 169643–169650
15Section 08, Charles B. O'KeeffeDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 408,644. Filing ↗machine: span 170730–170737
16Section 08, Donald A. DenkhausDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 386,269. Filing ↗machine: span 168544–168551
17Section 08, Tamar ThompsonDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 381,019. Filing ↗machine: span 171826–171833
18Section 08, David S. TierneyDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 381,019. Filing ↗machine: span 172905–172912
19Section 08, Richard J. DalyDEF 14A2025-04-110001193125-25-079097Section “Director Compensation”. As printed: 0. Filing ↗
20Section 02, Patrick J. McEnany 2025-11-21Form 42025-11-240001161697-25-000419Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Michael Kalb 2025-11-21Form 42025-11-240001161697-25-000418Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Michael Kalb 2025-11-21Form 42025-11-240001161697-25-000418Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Preethi Sundaram 2025-11-21Form 42025-11-240001161697-25-000422Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Brian Elsbernd 2025-11-21Form 42025-11-240001161697-25-000416Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Brian Elsbernd 2025-11-21Form 42025-11-240001161697-25-000416Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Richard J. Daly 2025-11-21Form 42025-11-240001161697-25-000413Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Jeffrey Del Carmen 2025-11-26Form 42025-11-280001161697-25-000430Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Jeffrey Del Carmen 2025-11-26Form 42025-11-280001161697-25-000430Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Jeffrey Del Carmen 2025-11-26Form 42025-11-280001161697-25-000430Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Patrick J. McEnany 2025-12-01Form 42025-12-030001161697-25-000432Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Patrick J. McEnany 2025-12-01Form 42025-12-030001161697-25-000432Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Patrick J. McEnany 2025-12-01Form 42025-12-030001161697-25-000432Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Preethi Sundaram 2025-12-08Form 42025-12-100001161697-25-000449Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Preethi Sundaram 2025-12-08Form 42025-12-100001161697-25-000449Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Molly Harper 2025-12-08Form 42025-12-100001161697-25-000446Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Molly Harper 2025-12-08Form 42025-12-100001161697-25-000446Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Patrick J. McEnany 2025-12-08Form 42025-12-100001161697-25-000447Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Jeffrey Del Carmen 2025-12-08Form 42025-12-100001161697-25-000443Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Jeffrey Del Carmen 2025-12-08Form 42025-12-100001161697-25-000443Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Tamar Thompson 2025-12-08Form 42025-12-100001161697-25-000450Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Steven Miller 2025-12-08Form 42025-12-100001161697-25-000448Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Brian Elsbernd 2025-12-08Form 42025-12-100001161697-25-000445Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Preethi Sundaram 2025-12-08Form 42025-12-100001161697-25-000449Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Jeffrey Del Carmen 2025-12-08Form 42025-12-100001161697-25-000443Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Brian Elsbernd 2025-12-08Form 42025-12-100001161697-25-000445Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Steven Miller 2025-12-08Form 42025-12-100001161697-25-000448Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Donald A. Denkhaus 2025-12-08Form 42025-12-100001161697-25-000444Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Patrick J. McEnany 2025-12-08Form 42025-12-100001161697-25-000447Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Tamar Thompson 2025-12-08Form 42025-12-100001161697-25-000450Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, David S. Tierney 2025-12-08Form 42025-12-100001161697-25-000451Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, David S. Tierney 2025-12-08Form 42025-12-100001161697-25-000451Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Donald A. Denkhaus 2025-12-08Form 42025-12-100001161697-25-000444Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Brian Elsbernd 2025-12-08Form 42025-12-100001161697-25-000445Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Molly Harper 2025-12-12Form 42025-12-160001161697-25-000462Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Molly Harper 2025-12-12Form 42025-12-160001161697-25-000462Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Molly Harper 2025-12-12Form 42025-12-160001161697-25-000462Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Molly Harper 2025-12-12Form 42025-12-160001161697-25-000462Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Molly Harper 2025-12-12Form 42025-12-160001161697-25-000462Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Richard J. Daly 2025-12-29Form 42025-12-300001161697-25-000488Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Patrick J. McEnany 2025-12-29Form 42025-12-300001161697-25-000493Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Patrick J. McEnany 2025-12-29Form 42025-12-300001161697-25-000493Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Molly Harper 2025-12-29Form 42025-12-300001161697-25-000492Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Steven Miller 2025-12-29Form 42025-12-300001161697-25-000494Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Steven Miller 2025-12-29Form 42025-12-300001161697-25-000494Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Preethi Sundaram 2025-12-29Form 42025-12-300001161697-25-000495Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, David S. Tierney 2025-12-29Form 42025-12-300001161697-25-000496Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Brian Elsbernd 2025-12-29Form 42025-12-300001161697-25-000491Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Donald A. Denkhaus 2025-12-29Form 42025-12-300001161697-25-000490Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Brian Elsbernd 2025-12-29Form 42025-12-300001161697-25-000491Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Preethi Sundaram 2025-12-29Form 42025-12-300001161697-25-000495Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Brian Elsbernd 2025-12-29Form 42025-12-300001161697-25-000491Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Donald A. Denkhaus 2025-12-29Form 42025-12-300001161697-25-000490Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Jeffrey Del Carmen 2025-12-29Form 42025-12-300001161697-25-000489Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jeffrey Del Carmen 2025-12-29Form 42025-12-300001161697-25-000489Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Richard J. Daly 2025-12-29Form 42025-12-300001161697-25-000488Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Richard J. Daly 2025-12-29Form 42025-12-300001161697-25-000488Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Patrick J. McEnany 2025-12-29Form 42025-12-300001161697-25-000493Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Molly Harper 2025-12-29Form 42025-12-300001161697-25-000492Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Preethi Sundaram 2025-12-29Form 42025-12-300001161697-25-000495Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, David S. Tierney 2025-12-29Form 42025-12-300001161697-25-000496Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jeffrey Del Carmen 2025-12-29Form 42025-12-300001161697-25-000489Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Richard J. Daly 2026-01-05Form 42026-01-060001161697-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Michael Kalb 2026-01-05Form 42026-01-060001161697-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Richard J. Daly 2026-01-05Form 42026-01-060001161697-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Michael Kalb 2026-01-05Form 42026-01-060001161697-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Richard J. Daly 2026-01-05Form 42026-01-060001161697-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Michael Kalb 2026-01-05Form 42026-01-060001161697-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Gregg Russo 2026-02-17Form 42026-02-190001161697-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Gregg Russo 2026-02-17Form 42026-02-190001161697-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Gregg Russo 2026-02-17Form 42026-02-190001161697-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, William T. Andrews 2026-06-03Form 42026-06-050001161697-26-000132Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, William T. Andrews 2026-06-03Form 42026-06-050001161697-26-000132Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Daniel J. Curran 2026-07-15Form 42026-07-170001161697-26-000172Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Daniel J. Curran 2026-07-15Form 42026-07-170001161697-26-000172Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, William T. Andrews 2026-07-15Form 42026-07-170001161697-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Molly Harper 2026-07-15Form 42026-07-170001161697-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, William T. Andrews 2026-07-15Form 42026-07-170001161697-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, William T. Andrews 2026-07-15Form 42026-07-170001161697-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Jeffrey Del Carmen 2026-07-15Form 42026-07-170001161697-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Gregg Russo 2026-07-15Form 42026-07-170001161697-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Tamar Thompson 2026-07-15Form 42026-07-170001161697-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Daniel J. Curran 2026-07-15Form 42026-07-170001161697-26-000172Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Michael Kalb 2026-07-15Form 42026-07-170001161697-26-000178Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, William T. Andrews 2026-07-15Form 42026-07-170001161697-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, Donald A. Denkhaus 2026-07-15Form 42026-07-170001161697-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Patrick J. McEnany 2026-07-15Form 42026-07-170001161697-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Steven Miller 2026-07-15Form 42026-07-170001161697-26-000180Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, David S. Tierney 2026-07-15Form 42026-07-170001161697-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Brian Elsbernd 2026-07-15Form 42026-07-170001161697-26-000176Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, William T. Andrews 2026-07-15Form 42026-07-170001161697-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Richard J. Daly 2026-07-15Form 42026-07-170001161697-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Preethi Sundaram 2026-07-15Form 42026-07-170001161697-26-000182Insider equity transaction reported since the proxy statement. Filing ↗
220Section 06, 2025 voteForm 8-K2025-05-230001193125-25-125872Item 5.07 · say-on-pay result. As reported: 92.73% (votes for as printed: 82,734,939). Filing ↗
221Section 06, 2024 voteForm 8-K2024-05-210001193125-24-144049Item 5.07 · say-on-pay result. As reported: 93.9% (votes for as printed: 84,194,484). Filing ↗
222Section 06, 2023 voteForm 8-K2023-08-250001193125-23-221544Item 5.07 · say-on-pay result. As reported: 96.15% (votes for as printed: 72,610,991). Filing ↗
223Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
224Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
225Section 09b board cost (computed)Computed——Cash 778,211 + equity 2,062,643 + all other 0 = 2,840,854, summed across the director compensation table rows.machine: formula: Σ = 2,840,854
226PTC Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗
227Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
228Corcept Therapeutics Incorporated, Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514
229Insmed Incorporated, Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
230Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
231Pacira BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
232Ultragenyx Pharmaceutical, Inc., Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceutical, Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
233Ani Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-090001023024-26-000039CEO total compensation as printed in Ani Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154
234Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
235Amphastar Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-130001297184-26-000023CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932
236Acadia Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗
237Dynavax Technologies Corporation, Section 10b CEO totalDEF 14A2025-04-170000930413-25-001273CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. Filing ↗
238Harmony Biosciences Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-030001104659-26-039449CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364
239Catalyst Pharmaceuticals (subject), Section 10b CEO totalDEF 14A2025-04-110001193125-25-079097CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. Filing ↗
240Ironwood Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191
241Collegium Pharmaceutical, Inc., Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
242Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗
243Section 10a, Amphastar Pharmaceuticals, Inc. reciprocityDEF 14A—0001297184-26-000023Amphastar Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
244Section 10a, Dynavax Technologies Corporation reciprocityDEF 14A—0000930413-25-001273Dynavax Technologies Corporation's most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
245Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
246Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
247Section 10a, Ironwood Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-050325Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
248Section 10a, Pacira BioSciences, Inc. reciprocityDEF 14A—0001104659-26-050353Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
249Section 10a, PTC Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
250Section 10a, Insmed Incorporated reciprocityDEF 14A—0001104506-26-000022Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
251Section 10a, Collegium Pharmaceutical, Inc. reciprocityDEF 14A—0001628280-26-024063Collegium Pharmaceutical, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗
252Section 10a, Ultragenyx Pharmaceutical, Inc. reciprocityDEF 14A—0001308179-26-000174Ultragenyx Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗
253Section 10a, Ani Pharmaceuticals, Inc. reciprocityDEF 14A—0001023024-26-000039Ani Pharmaceuticals, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗
254Section 10a, Acadia Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-174163Acadia Pharmaceuticals Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗
255Section 10a, Harmony Biosciences Holdings, Inc. reciprocityDEF 14A—0001104659-26-039449Harmony Biosciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.